Product Description
Merck is developing MK-4621 as a treatment for Advanced Solid Tumors. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03739138)
Mechanisms of Action: RIG1 Activator
Novel Mechanism: Yes
Modality: Device
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Four 50 mg Tablets | N/A |
Not yet recruiting |
Type 2 Diabetes |
2021-07-01 |
|
| MK-4621-002 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2021-03-02 |
|
| A Phase I/II trial of intralesional administration of RGT100 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2018-05-18 |
|
| MK-4621-001/RGT100-001 | P2 |
Terminated |
Oncology Solid Tumor Unspecified |
2018-05-18 |
51% |